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INTEGRATIVE NEUROSCIENCE
of damaged components of the nervous 
system, neuroplasticity, neuroprotection 
and neuromodulation,  vasculogenesis, 
and recovery mechanisms of immune reg-
ulation (Fornai et al., 2008; IANR, 2009; 
Mitrecic´ et al., 2009; Huang et al., 2010). 
Embryonic or neuronal stem cells hardly 
replace motor neuron in ALS and also are 
difficult to have useful functions as peo-
ple expect. Otherwise, transplanted cells 
can serve as a source of trophic factors 
providing neuroprotection, slowing down 
neuronal degeneration, and disease progres-
sion. Presently, cell–based neurorestorative 
treatment has become a new trend (Huang, 
2010). Rapidly increasing worldwide data 
have proven that it has a pivotal therapeu-
tic value in ALS (see Tables 1 and 2; Chen 
et al., 2012). So neruoprotection is one of 
the most functional neurorestorative strat-
egies for ALS; unfortunately Dr. Piepers 
fully ignored most of the progress in this 
research field.
What ideal expectation of 
treatment is and What current 
medicine can do for als?
To attenuate the rate of deterioration 
should be considered and encouraged as 
the main aim at the current time, because 
the cure has not yet been made available 
so far. So any improvement is very impor-
tant for patients with ALS. Based on Dr. 
Piepers’ paper, we at least found three 
out of a total of seven patients who had 
reversed their functions after our treat-
ment. Our recent study, multiple trans-
plantations for ALS shows that every 
single treatment could make functional 
improvement for patients (Table 3; Chen 
et al., 2012). These essential findings 
should be translated as highlighted posi-
tive results because specialists in the ALS 
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introduction
Amyotrophic lateral sclerosis (ALS) is a 
progressive, fatal, neurodegenerative dis-
ease caused by the degeneration of motor 
neurons, the nerve cells in the central nerv-
ous system that control voluntary muscle 
movement. Death due to respiratory failure 
occurs typically 2–5 years after disease onset 
(Suzuki et al., 2007). Our basic and clinical 
studies have proven that OECs have neu-
roprotective effect and can improve quality 
of life and prolong surviving time (Huang 
et al., 2007, 2008; Chen et al., 2007, 2012; Li 
et al., 2011). Dr. Piepers (Piepers and van den 
Berg, 2010) published a paper to make com-
ment on our work, in which there were some 
wrong viewpoints and errors. Also there may 
be someone sharing same viewpoints with his 
paper. In order to avoid misleading readers, it 
is our irresistible duty to tell people the truth 
what happened about treatment study, show 
more evidences, and facts of development for 
this disease. Herein, we encourage people to 
read his original paper with our thoughts in 
mind. We strongly believe that scientific truth 
should rely on facts, but not conjecture.
“these therapies aim at neuronal 
replacement or use embryonic or 
neuronal stem cells to prevent 
dysfunctional motor neurons 
from dying” is correct?
In fact, the mechanisms for neurorestora-
tion in ALS are very complex, which lie on 
neural regeneration, repair, and replacement 
study community around the whole world 
know there is no way to reverse the clini-
cal course of ALS through routine treat-
ment including Rilutek. People should not 
require current medicine to get treatment 
results as their ideal expectation for some 
untreatable diseases such as ALS.
Where should the cells be 
transplanted into?
We can understand why Dr. Piepers said 
that “it is difficult to understand how focal 
injection of OECs into the corona radiata 
of ALS patients would result in improved 
function of motor neurons that are not in 
close proximity to the injection site.” We 
compared two ways by transplanting cells 
into spinal cord or brain; and there was 
no difference of functional improvement 
between two methods (Chen et al., 2007). 
We are also doing experimental study 
which will be published soon. People will 
know more about the progress in this field 
from our current experimental study, that 
is, OEC transplantation in corona radi-
ate prolongs the survival of SOD1–G93A 
rats with protection to not only the upper 
motor neurons but lower motor neurons 
in cornu anterius medullae spinalis as 
well.
“it has been shoWn that injecting 
stem cells into the spinal cord of 
als patients is technically 
feasible and safe” is correct?
It is well known that the spinal cord sur-
gery under the general anesthesia has more 
risks in ALS patients, so we have improved 
our treatment from the initial intraspinal 
cord transplantation since over 5 years 
ago. Our clinical study proved that local 
anesthesia and stereotactic procedure has 
much less body damage for ALS patients 
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Table 1 | Selected preclinical literatures of cell-based therapy for ALS (data from Pubmed; modified from 5).
Authors Country Year Publications
Demierre et al. 
(1990)
Switzerland Demierre et al. (1990) Grafting of embryonic motoneurons into adult spinal cord and brain
Clowry et al. 
(1991)
UK Clowry et al. (1991) Transplants of embryonic motoneurones to adult spinal cord: survival and innervation abilities
Sagot et al. 
(1995)
Switzerland Sagot et al. (1995) Polymer encapsulated cell lines genetically engineered to release ciliary neurotrophic factor 
(CNTF) can slow down progressive motor neuronopathy in the mouse
Cooper et al. 
(1996)
France Cooper et al. (1996) Intraspinal injection of embryonic neurons maintains muscle phenotype in adult chronic spinal 
rats
Mohajeri et al. 
(1999)
USA Mohajeri et al. (1999) Intramuscular grafts of myoblasts genetically modified to secrete glial cell line-derived 
neurotrophic factor prevent motoneuron loss and disease progression in familial ALS mice
Ende et al. 
(2000)
USA Ende et al. (2000) Human umbilical cord blood effect on SOD mice (plus 800 cGy of irradiation)
Garbuzova-Davis 
et al. (2002)
USA Garbuzova-Davis et al. 
(2002)
Positive effect of transplantation of hNT neurons (NTera 2/D1 cell line) in a model of familial 
ALS




USA Garbuzova-Davis et al. 
(2003)
Intravenous administration of human umbilical cord blood cells in a mouse model of 
amyotrophic lateral sclerosis: distribution, migration, and differentiation
Corti et al. 
(2004)
Italy Corti et al. (2004) Wild-type bone marrow cells ameliorate the phenotype of SOD1–G93A mice and contribute 
to CNS, heart, and skeletal muscle tissues
Gao et al. (2005) USA Gao et al. (2005) Human neural stem cell-derived cholinergic neurons innervate muscle in motoneuron 
deficient adult rats
Li et al. (2005) USA Li et al. (2005) Fate of immortalized human neuronal progenitor cells transplanted in rat spinal cord
Klein et al. 
(2005)
USA Klein et al. (2005) GDNF delivery using human neural progenitor cells in a rat model of ALS
Hemendinger 
et al. (2005)
USA Hemendinger et al. 
(2005)
Sertoli cells improve survival of motor neurons in SOD1 transgenic mice
Corti et al. 
(2006)
Italy Corti et al. (2006) Transplanted ALDHhiSSClo neural stem cells generate motor neurons and delay disease 
progression of nmd mice, an animal model of SMARD1
Solomon et al. 
(2006)
Canada Solomon et al. (2006) Origin and distribution of bone marrow-derived cells in the central nervous system in ALS 
mice
Yan et al. (2006) USA Yan et al. (2006) Combined immunosuppressive agents or CD4 antibodies prolong survival of human neural 
stem cell grafts and improve disease outcomes in ALS transgenic mice
Salah-Mohellibi 
et al. (2006)
France Salah-Mohellibi et al. 
(2006)
Bone marrow transplantation attenuates the myopathic phenotype of a muscular mouse 
model of spinal muscular atrophy
Huang et al. 
(2006)
China Huang et al. (2006) Effect of transplantation of wild-type bone marrow stem cells in familial ALS mice
Xu et al. (2006) USA Xu et al. (2006) Human neural stem cell grafts ameliorate motor neuron disease in SOD1 transgenic rats
Lim et al. (2006) Australia Lim et al. (2006) Derivation of motor neurons from three clonal human embryonic stem cell lines
Suzuki et al. 
(2007)
USA Suzuki et al. (2007) GDNF secreting human neural progenitor cells protect dying motor neurons, but not their 
projection to muscle, in a rat model of familial ALS
Zhao et al. 
(2007)
China Zhao et al. (2007) Human mesenchymal stromal cells ameliorate the phenotype of SOD1–G93A ALS mice
Christou et al. 
(2007)
UK Christou et al. (2007) Embryonic stem cells and prospects for their use in regenerative medicine approaches to 
motor neuron disease
Martin and Liu 
(2007)
USA Martin and Liu (2007) Adult olfactory bulb neural precursor cell grafts provide temporary protection from motor 
neuron degeneration, improve motor function, and extend survival in ALS mice
(Continued)
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Authors Country Year Publications
Kang and Rivest 
(2007)
Canada Kang and Rivest 
(2007)
MyD88-deficient bone marrow cells accelerate onset and reduce survival in ALS mice
Garbuzova-Davis 
et al. (2008)
USA Garbuzova-Davis et al. 
(2008)
Human umbilical cord blood treatment in ALS mice: optimization of cell dose
Vercelli et al. 
(2008)
Italy Vercelli et al. (2008) Human mesenchymal stem cell transplantation extends survival, improves motor 
performance and decreases neuroinflammation in ALS mice
Suzuki et al. 
(2008)
USA Suzuki et al. (2008) Direct muscle delivery of GDNF with human mesenchymal stem cells improves motor 
neuron survival and function in familial ALS rats
Beers et al. 
(2008)
USA Beers et al. (2008) CD4+ T cells support glial neuroprotection, slow disease progression, and modify glial 
morphology in an animal model of inherited ALS
Lepore et al. 
(2008)
USA Lepore et al. (2008) Focal transplantation-based astrocyte replacement is neuroprotective in ALS. [lineage-
restricted astrocyte precursors, glial-restricted precursors (GRPs)]
Xu et al. (2009) USA Xu et al. (2009) Human neural stem cell grafts in the spinal cord of SOD1 transgenic rats: differentiation and 
structural integration into the segmental motor circuitry
Zhang et al. 
(2009)
China Zhang et al. (2009) Multiple administrations of human marrow stromal cells through cerebrospinal fluid prolong 
survival in ALS transgenic mice
Hwang et al. 
(2009)
Korea Hwang et al. (2009) Intrathecal transplantation of human neural stem cells overexpressing VEGF provide 
behavioral improvement, disease onset delay, and survival extension in transgenic ALS mice
López-González 
et al. (2009)
México López-González et al. 
(2009)
Transient recovery in familial ALS rats after transplantation of motor neurons derived from 
mouse embryonic stem cells
Kim et al. (2010) Korea Kim et al. (2010) Dose-dependent efficacy of ALS-human mesenchymal stem cells transplantation into 
cisterna magna in SOD1–G93A ALS mice
Guo et al. (2010) USA Guo et al. (2010) Characterization of a human fetal spinal cord stem cell line, NSI-566RSC, and its induction to 
functional motoneurons
Gu et al. (2010) China Gu et al. (2010) Human adipose-derived stem cells enhance the glutamate uptake function of GLT1 in 
SOD1(G93A)-bearing astrocytes
Mitrecic´ et al. 
(2010)
Belgium Mitrecic´ et al. (2010) Distribution, differentiation, and survival of intravenously administered neural stem cells in a 
rat model of amyotrophic lateral sclerosis
Rizvanov et al. 
(2011)
Russia Rizvanov et al. (2011) Genetically modified human umbilical cord blood cells expressing vascular endothelial growth 
factor and fibroblast growth factor 2 differentiate into glial cells after transplantation into 
amyotrophic lateral sclerosis transgenic mice
Xu et al. (2011) USA Xu et al. (2011) Dual transplantation of human neural stem cells into cervical and lumbar cord ameliorates 
motor neuron disease in SOD1 transgenic rats
Forostyak et al. 
(2011)
Czech Forostyak et al. (2011) Mesenchymal stromal cells prolong the lifespan in a rat model of ALS
Pastor et al. 
(2011)
Spain Pastor et al. (2011) Comparative effects between bone marrow and mesenchymal stem cell transplantation in 
GDNF expression and motor function recovery in ALS mouse
Lunn et al. (2011) USA Lunn et al. (2011) Stem cell technology for motor neuron diseases
Sanberg et al. 
(2011)
USA Sanberg et al. (2011) Treatment of neurodegenerative disorders using umbilical cord blood and menstrual 
blood-derived stem cells
Table 1 | Continued
than general anesthesia and open spinal 
surgery (Chen et al., 2007). We suggest 
that Dr. Piepers should do more clini-
cal investigations or get clinical experi-
ence before he comments or discusses on 




The application of immunosuppressant 
remains controversial after cell transplanta-
tion into the brain and/or spinal cord. In addi-
tional, some of the ALS patients are too weak 
to tolerate the drugs. Most recently, OECs were 
able to stay alive for at least 12–24 months 
which has been proven through two autopsies 
by Italian physicians (Giordana et al., 2010).
In summary, to talk by conjecture is 
a simple process; however, to really help 
patients with ALS to improve their neuro-
logical functions and quality of life must face 
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sclerosis. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 
21, 961–966.
Choi, M. R., Kim, H. Y., Park, J. Y., Lee, T. Y., Baik, C. S., 
Chai, Y. G., Jung, K. H., Park, K. S., Roh, W., Kim, K. 
S., and Kim, S. H. (2010). Selection of optimal passage 
of bone marrow-derived mesenchymal stem cells for 
stem cell therapy in patients with amyotrophic lateral 
sclerosis. Neurosci. Lett. 472, 94–98.
Christou, Y. A., Moore, H. D., Shaw, P. J., and Monk, P. N. 
(2007). Embryonic stem cells and prospects for their 
use in regenerative medicine approaches to motor neu-
rone disease. Neuropathol. Appl. Neurobiol. 33, 485–498.
Clowry, G., Sieradzan, K., and Vrbová, G. (1991). 
Transplants of embryonic motoneurones to adult 
spinal cord, survival and innervation abilities. Trends 
Neurosci. 14, 355–357.
Cooper, R. N., Feraboli–Lohnherr, D., Butler–Browne, 
G., Orsal, D., Gimenez, Y., Ribotta, M., and Privat, A. 
(1996). Intraspinal injection of embryonic neurons 
maintains muscle phenotype in adult chronic spinal 
rats. J. Neurosci. Res. 46, 324–329.
Beers, D. R., Henkel, J. S., Zhao, W., Wang, J., and Appel, S. 
H. (2008). CD4+ T cells support glial neuroprotection, 
slow disease progression, and modify glial morphol-
ogy in an animal model of inherited ALS. Proc. Natl. 
Acad. Sci. U.S.A. 105, 15558–15563.
Cashman, N., Tan, L. Y., Krieger, C., Mädler, B., Mackay, 
A., Mackenzie, I., Benny, B., Nantel, S., Fabros, M., 
Shinobu, L., Yousefi, M., and Eisen, A. (2008). Pilot 
study of granulocyte colony stimulating factor 
(G–CSF)–mobilized peripheral blood stem cells in 
amyotrophic lateral sclerosis (ALS). Muscle Nerve 
37, 620–625.
Chen, L., Chen, D., Xi, H., Wang, Q., Liu, Y., Zhang, F., 
Wang, H., Ren, Y., Xiao, J., Wang, Y., and Huang, H. 
(2012). Olfactory ensheathing cell neurorestorotherapy 
for amyotrophic lateral sclerosis patients, benefits from 
multiple transplantations. Cell Transplant. 20. (in press).
Chen, L., Huang, H., Zhang, J., Zhang, F., Liu, Y., Xi, H., 
Wang, H., Gu, Z., Song, Y., Li, Y., and Tan, K. (2007). 
Short–term outcome of olfactory ensheathing cells 
transplantation for treatment of amyotrophic lateral 
hardships and challenges. The community 
should encourage any efforts to discover 
effective therapeutic strategies globally. 
Fortunately, now clinical studies already 
showed that cell therapy could restore 
patients’ neurological functions by neuro-
protection or some other mechanisms.
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